{"id":69874,"date":"2026-07-13T16:44:04","date_gmt":"2026-07-13T08:44:04","guid":{"rendered":"https:\/\/flcube.com\/?p=69874"},"modified":"2026-07-13T16:44:05","modified_gmt":"2026-07-13T08:44:05","slug":"sisram-medical-restructures-daxibotulinumtoxina-partnership-with-fosun-wanbang-through-new-sublicense-and-promotion-services-agreements","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69874","title":{"rendered":"Sisram Medical Restructures DaxibotulinumtoxinA Partnership with Fosun Wanbang Through New Sublicense and Promotion Services Agreements"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Sisram Medical Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1696:HKG\">HKG: 1696<\/a>) announced that the company has entered into a <strong>new sublicense agreement<\/strong> and a <strong>new promotion services agreement<\/strong> with <strong>Fosun Wanbang<\/strong> regarding <strong>DaxibotulinumtoxinA-lanm for injection<\/strong>, completely replacing the original commercial distribution cooperation agreement established in September 2025.<\/p>\n\n\n\n<h2 id=\"h-agreement-restructuring-details\" class=\"wp-block-heading\">Agreement Restructuring Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Sisram Medical Ltd. (HKG: 1696); Fosun Wanbang<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>DaxibotulinumtoxinA-lanm for injection (next-generation Type A botulinum toxin)<\/td><\/tr><tr><td><strong>New Agreements<\/strong><\/td><td>Sublicense agreement; Promotion services agreement<\/td><\/tr><tr><td><strong>Previous Agreement<\/strong><\/td><td>Commercial distribution cooperation agreement (September 2025)<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>10 Jul 2026<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Chinese Mainland, Hong Kong, and Macau<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">This strategic restructuring reflects an evolution in the partnership model, potentially optimizing commercial responsibilities and revenue sharing for the premium neuromodulator product.<\/p>\n\n\n\n<h2 id=\"h-product-profile-amp-innovation\" class=\"wp-block-heading\">Product Profile &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> DaxibotulinumtoxinA for injection<\/li>\n\n\n\n<li><strong>Developer:<\/strong> Revance Therapeutics, Inc. (U.S.-based)<\/li>\n\n\n\n<li><strong>Key Innovation:<\/strong> World&#8217;s first and only neuromodulator formulated with proprietary peptide technology<\/li>\n\n\n\n<li><strong>Composition:<\/strong> Highly purified 150kD botulinum toxin type A<\/li>\n\n\n\n<li><strong>Indications:<\/strong> Both therapeutic and aesthetic applications<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Enhanced duration of effect and precision compared to conventional botulinum toxins<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">DaxibotulinumtoxinA represents a significant advancement in neuromodulator technology, offering potential competitive advantages in both duration and patient satisfaction metrics.<\/p>\n\n\n\n<h2 id=\"h-original-partnership-structure-september-2025\" class=\"wp-block-heading\">Original Partnership Structure (September 2025)<\/h2>\n\n\n\n<h3 id=\"h-sisram-medical-tianjin-responsibilities\" class=\"wp-block-heading\">Sisram Medical Tianjin Responsibilities<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Commercialization strategy and execution<\/li>\n\n\n\n<li>Marketing and brand development<\/li>\n\n\n\n<li>Medical education and training programs<\/li>\n\n\n\n<li>Commercial planning and market analysis<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-fosun-wanbang-jiangsu-responsibilities\" class=\"wp-block-heading\">Fosun Wanbang (Jiangsu) Responsibilities<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Product import and procurement<\/li>\n\n\n\n<li>Customs clearance and statutory inspection<\/li>\n\n\n\n<li>Warehousing and transportation logistics<\/li>\n\n\n\n<li>Commercial channel distribution<\/li>\n\n\n\n<li>General distribution network management<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The original structure divided responsibilities between commercial\/marketing functions and supply chain\/logistics operations.<\/p>\n\n\n\n<h2 id=\"h-revised-partnership-structure-july-2026\" class=\"wp-block-heading\">Revised Partnership Structure (July 2026)<\/h2>\n\n\n\n<h3 id=\"h-new-sublicense-agreement\" class=\"wp-block-heading\">New Sublicense Agreement<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Grants Sisram Medical enhanced commercial rights within the territory<\/li>\n\n\n\n<li>Clarifies intellectual property usage and sublicensing terms<\/li>\n\n\n\n<li>Establishes updated royalty and revenue sharing mechanisms<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-new-promotion-services-agreement\" class=\"wp-block-heading\">New Promotion Services Agreement<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Formalizes Sisram Medical&#8217;s role in promotional activities<\/li>\n\n\n\n<li>Defines scope of marketing and medical education services<\/li>\n\n\n\n<li>Outlines performance metrics and service level agreements<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The restructuring likely provides Sisram Medical with greater control over commercial strategy while maintaining Fosun Wanbang&#8217;s supply chain expertise.<\/p>\n\n\n\n<h2 id=\"h-licensing-background-amp-rights-chain\" class=\"wp-block-heading\">Licensing Background &amp; Rights Chain<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Original Developer:<\/strong> Revance Therapeutics, Inc.<\/li>\n\n\n\n<li><strong>Regional Licensee:<\/strong> Fosun Pharma (parent company of Fosun Wanbang)<\/li>\n\n\n\n<li><strong>License Scope:<\/strong> Exclusive rights to use, import, sell, and commercialize (excluding manufacturing)<\/li>\n\n\n\n<li><strong>Territory:<\/strong> Chinese Mainland, Hong Kong, and Macau<\/li>\n\n\n\n<li><strong>Indications:<\/strong> Both therapeutic and aesthetic applications<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Fosun Pharma&#8217;s original licensing agreement with Revance established the foundation for commercial development in Greater China, with subsequent partnerships enabling specialized commercial execution.<\/p>\n\n\n\n<h2 id=\"h-market-context-amp-competitive-landscape\" class=\"wp-block-heading\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Traditional Botulinum Toxins<\/th><th>DaxibotulinumtoxinA Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>Duration of Effect<\/strong><\/td><td>3-4 months typically<\/td><td>Extended duration (6+ months reported)<\/td><\/tr><tr><td><strong>Onset of Action<\/strong><\/td><td>2-7 days<\/td><td>Comparable or improved onset<\/td><\/tr><tr><td><strong>Precision<\/strong><\/td><td>Standard diffusion profile<\/td><td>Enhanced targeting with peptide technology<\/td><\/tr><tr><td><strong>Patient Satisfaction<\/strong><\/td><td>Established track record<\/td><td>Potential for superior outcomes<\/td><\/tr><tr><td><strong>Price Positioning<\/strong><\/td><td>Competitive pricing<\/td><td>Premium positioning justified by innovation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The Chinese botulinum toxin market is projected to reach RMB 15-20 billion by 2028, driven by growing aesthetic medicine adoption and expanding therapeutic applications.<\/p>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Commercial Optimization:<\/strong> Restructured agreements likely improve commercial efficiency and profitability<\/li>\n\n\n\n<li><strong>Market Positioning:<\/strong> Enhanced focus on premium neuromodulator segment<\/li>\n\n\n\n<li><strong>Partnership Evolution:<\/strong> Demonstrates adaptive collaboration between Sisram and Fosun entities<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Greater commercial control may translate to improved margin capture<\/li>\n\n\n\n<li><strong>Competitive Response:<\/strong> Positions partnership to effectively compete against established botulinum toxin brands<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding commercial performance, market adoption, and partnership outcomes. Actual results may differ due to risks including regulatory requirements, market competition, and consumer preferences.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026071001350_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026071001350_c.\"><\/object><a id=\"wp-block-file--media-55f79bbe-1afa-4ca3-b441-e38cbf7a3453\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026071001350_c.pdf\">2026071001350_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026071001350_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-55f79bbe-1afa-4ca3-b441-e38cbf7a3453\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sisram Medical Ltd. (HKG: 1696) announced that the company has entered into a new sublicense&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[1180,100,357],"class_list":["post-69874","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-hkg-1696","tag-medical-aesthetics","tag-sisram-medical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sisram Medical Restructures DaxibotulinumtoxinA Partnership with Fosun Wanbang Through New Sublicense and Promotion Services Agreements - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sisram Medical Ltd. (HKG: 1696) announced that the company has entered into a new sublicense agreement and a new promotion services agreement with Fosun Wanbang regarding DaxibotulinumtoxinA-lanm for injection, completely replacing the original commercial distribution cooperation agreement established in September 2025.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69874\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sisram Medical Restructures DaxibotulinumtoxinA Partnership with Fosun Wanbang Through New Sublicense and Promotion Services Agreements\" \/>\n<meta property=\"og:description\" content=\"Sisram Medical Ltd. (HKG: 1696) announced that the company has entered into a new sublicense agreement and a new promotion services agreement with Fosun Wanbang regarding DaxibotulinumtoxinA-lanm for injection, completely replacing the original commercial distribution cooperation agreement established in September 2025.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69874\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-13T08:44:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-13T08:44:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69874#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69874\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sisram Medical Restructures DaxibotulinumtoxinA Partnership with Fosun Wanbang Through New Sublicense and Promotion Services Agreements\",\"datePublished\":\"2026-07-13T08:44:04+00:00\",\"dateModified\":\"2026-07-13T08:44:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69874\"},\"wordCount\":573,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 1696\",\"Medical aesthetics\",\"Sisram Medical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69874#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69874\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69874\",\"name\":\"Sisram Medical Restructures DaxibotulinumtoxinA Partnership with Fosun Wanbang Through New Sublicense and Promotion Services Agreements - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-13T08:44:04+00:00\",\"dateModified\":\"2026-07-13T08:44:05+00:00\",\"description\":\"Sisram Medical Ltd. (HKG: 1696) announced that the company has entered into a new sublicense agreement and a new promotion services agreement with Fosun Wanbang regarding DaxibotulinumtoxinA-lanm for injection, completely replacing the original commercial distribution cooperation agreement established in September 2025.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69874#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69874\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69874#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sisram Medical Restructures DaxibotulinumtoxinA Partnership with Fosun Wanbang Through New Sublicense and Promotion Services Agreements\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sisram Medical Restructures DaxibotulinumtoxinA Partnership with Fosun Wanbang Through New Sublicense and Promotion Services Agreements - Insight, China&#039;s Pharmaceutical Industry","description":"Sisram Medical Ltd. (HKG: 1696) announced that the company has entered into a new sublicense agreement and a new promotion services agreement with Fosun Wanbang regarding DaxibotulinumtoxinA-lanm for injection, completely replacing the original commercial distribution cooperation agreement established in September 2025.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69874","og_locale":"en_US","og_type":"article","og_title":"Sisram Medical Restructures DaxibotulinumtoxinA Partnership with Fosun Wanbang Through New Sublicense and Promotion Services Agreements","og_description":"Sisram Medical Ltd. (HKG: 1696) announced that the company has entered into a new sublicense agreement and a new promotion services agreement with Fosun Wanbang regarding DaxibotulinumtoxinA-lanm for injection, completely replacing the original commercial distribution cooperation agreement established in September 2025.","og_url":"https:\/\/flcube.com\/?p=69874","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-13T08:44:04+00:00","article_modified_time":"2026-07-13T08:44:05+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69874#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69874"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sisram Medical Restructures DaxibotulinumtoxinA Partnership with Fosun Wanbang Through New Sublicense and Promotion Services Agreements","datePublished":"2026-07-13T08:44:04+00:00","dateModified":"2026-07-13T08:44:05+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69874"},"wordCount":573,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 1696","Medical aesthetics","Sisram Medical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69874#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69874","url":"https:\/\/flcube.com\/?p=69874","name":"Sisram Medical Restructures DaxibotulinumtoxinA Partnership with Fosun Wanbang Through New Sublicense and Promotion Services Agreements - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-13T08:44:04+00:00","dateModified":"2026-07-13T08:44:05+00:00","description":"Sisram Medical Ltd. (HKG: 1696) announced that the company has entered into a new sublicense agreement and a new promotion services agreement with Fosun Wanbang regarding DaxibotulinumtoxinA-lanm for injection, completely replacing the original commercial distribution cooperation agreement established in September 2025.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69874#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69874"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69874#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sisram Medical Restructures DaxibotulinumtoxinA Partnership with Fosun Wanbang Through New Sublicense and Promotion Services Agreements"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69874","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69874"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69874\/revisions"}],"predecessor-version":[{"id":69876,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69874\/revisions\/69876"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69874"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69874"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69874"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}